{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"EP_1586330_A1","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"083-025-453-433-266"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11656,"type":"PATENT","title":"University of Goettingen - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":761,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8322,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:uni* goettingen
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 656
Search Applicants and Owners separately:uni* goettingen
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 656
a) either residue M at position 1 and residue A at position 8 remain unchanged, or that
b) residue L at position 2 and residue V at position 9 remain unchanged,and that one, two or three, more preferably one or two, even more preferably one, of the other amino acid residues are exchanged for another amino acid residue, preferably wherein the amino acid exchange is a semi-conservative exchange, more preferably wherein the amino acid exchange is a conservative exchange, and/or wherein one or two amino acid residues can be inserted or deleted at any position between amino acid residue 1 and 8 in the case of alternative a) or amino acid residue 2 and 9 in the case of alternative b), wherein preferably said insertion is an insertion of one or two, more preferably one, amino acid residues at position 5 or 6, or wherein preferably said deletion is a deletion of one or two, more preferably one, amino acid residues at position 5 or 6."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["Use of any one of claims 1 to 3, particularly use of claim 2, wherein the first and/or second peptide is selected from the group consisting of SEQ ID NO:1-97."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["Use of any one of the preceding claims, wherein said first peptide with defined homology to SEQ ID NO:1 (HERV K-MEL) and/or said composition comprising said first peptide sequence is comprised in a vaccine and said vaccine is selected from the group consisting of the yellow fever vaccine, the Japanese encephalitis B vaccine, the Venezuelan equine encephalitis vaccine, the typhoid fever vaccine, the cholera vaccine, the rickettsia typhi vaccine, the pneumococci vaccine, the Friedmann vaccine (Mycobacterium chelonae), the vaccine against respiratory syncytial virus, the vaccine against pertussis, the vaccine against tick borne encephalitis, the Coley's toxin vaccine, the vaccine against Q-fever, the vaccine against brucella, the vaccine against anthrax, the vaccine against plague and the modified vaccinia vaccine Ankara (MVA), preferably selected from the group consisting of the yellow fever vaccine, the Japanese encephalitis B vaccine, the Venezuelan equine encephalitis vaccine, the typhoid fever vaccine, the cholera vaccine and the rickettsia typhi vaccine, and most preferably the yellow fever vaccine."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["Use any one of the preceding claims, wherein the vaccine is to be administered to a human subject above age 10, wherein the human subject has previously been vaccinated as a child with a vaccine according to claims 23 or 24 or with smallpox- or BCG-vaccine."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["Use of any one of claims 1-7, wherein the vaccine is to be administered to a child below age 2 years, preferably to a baby below age 1 year."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["Use of claim 9, wherein the vaccine has further been adapted so as to be administrable to a child below age 2 years, preferably to a baby below age 1 year."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["Method of vaccinating a subject for the prophylaxis of a disease as specified in any one of claims 1 to 3, preferably wherein the disease is a malignancy, more preferably wherein the malignancy is melanoma, wherein the method comprises the step of administering a first peptide as defined in claim 1, preferably as defined in claim 4 or alternatively as defined in claim 5, and/or a composition comprising said peptide sequence to a subj ect."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["Method of claim 11, wherein the subject is a human subject."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["Method of claims 11 or 12, wherein said peptide is administered to a child below age 2 years, preferably to a baby below age 1 year."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["Peptide as defined in claims 4 and/or 5 for use in vaccination for the prevention of a malignancy, wherein the peptide does not have the peptide sequence SEQ ID NO:1."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["Peptide of claim 14, wherein the peptide is selected from the group consisting of SEQ ID NO:3-97."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["Peptide of any one of claims 14 to 15, wherein the peptide has a length of from 8 to 12 amino acid residues."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["Peptide of any one of claims 14 to 16, wherein the peptide is further coupled to a carrier polypeptide, preferably to a polypeptide derived from tetanus toxoid or choleratoxin."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["Peptide of any one of claims 14 to 17, wherein the peptide is capable of being presented by the HLA A2 or another frequently occurring HLA class I molecule."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["Peptide of any one of claims 14 to 18, wherein the peptide comprises an anchor sequence for presentation by HLA A2 class I."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["Polypeptide comprising a peptide sequence as defined in claims 4 and/or 5 for use in vaccination for the prevention of a malignancy wherein said polypeptide is a fusion polypeptide which is not a naturally occurring polypeptide."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["Polypeptide comprising a peptide sequence as defined in claims 4 and/or 5 for use in vaccination for the prevention of a malignancy wherein said polypeptide is selected from the group consisting of SEQ ID NO: 3-97, preferably wherein the polypeptide is derived from Mycobacterium bovis, Mycobacterium tuberculosis, vaccinia virus, Staphylococcus aureus, yellow fever virus, Chlamydia pneumoniae, Chlamydia trachomatis, Entamoeba histolytica, Giardia lamblia, Haemophilus ducreyi, Japanese encephalitis B, Klebsiella pneumoniae, Leishmania donovani, Moraxella catarrhalis, Mycobacterium leprae, Pasteurella multocida, Pseudomonas aeruginosa, Salmonella typhi, Serratia marcescens, Shigella flexneri, Treponema pallidum, Venezuelan equine encephalitis virus, Vibrio cholerae, Vibrio parahaemolyticus, Yersinia enterocolitica, Bartonella bacilliformis, Bordetella pertussis, Brucella mellitensis, Fusobacterium nucleatum, Haemophilus influenzae, Leishmania major, Listeria monocytogenes, Neisseria gonorrhoe, Neisseria meningitides, orf-virus, Pasteurella multocida, Pneumocystis carinii, Proteus vulgaris, Pseudomonas aeruginosa Rickettsia rickettsii, Sahnonella typhi, Salmonella enterica, Streptococcus agalactiae, Streptococcus pyogenes, Tick-borne-encephalitis virus, Trichomonas vaginalis, Toxoplasma gondii, Trypanosoma gambiense, Yersinia pestis, Ajellomyces capsulatus, Babesisa bovis, Bacillus anthracis, Bacteroides thetaiotaomicron, Bacteroides fragilis, campylobacter jejuni, Clostridium tetani, Corynebacterium diphtheriae, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Giardia lamblia, Helicobacter pylori, Legionella pneumophila, Leptospira interrogans, Listeria innocua, Molluscum contagiosum, Mycobacterium fortuitum-chelonae, Mycobacterium marinum, Mycobacterium leprae, Mycoplasma penetrans, Pasteurella multocida, Plasmodium falciparum, respiratory syncytial virus, Tropheryma whippeli, Trypanosoma brucei, Trypanosoma cruzi, Vibrio parahaemolyticus, Vibrio vulnificus, Yersinis pestis, more preferably wherein the polypeptide is derived from Mycobacterium bovis, Mycobacterium tuberculosis, vaccinia virus, Staphylococcus aureus, Yellow fever virus, Chlamydia pneumoniae, Chlamydia trachomatis, Entamoeba histolytica, Giardia lamblia, Haemophilus ducreyi, Japanese encephalitis B, Klebsiella pneumoniae, Leishmania donovani, Moraxella catarrhalis, Mycobacterium leprae, Pasteurella multocida, Pseudomonas aeruginosa, Salmonella typhi, Serratia marcescens, Shigella flexneri, Treponema pallidum, Venezuelan equine encephalitis virus, Vibrio cholerae, Vibrio parahaemolyticus and Yersinia enterocolitica , most preferably wherein the polypeptide is derived from Mycobacterium bovis, Mycobacterium tuberculosis, vaccinia virus, Staphylococcus aureus and yellow fever virus"],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["Composition comprising a peptide or polypeptide according to any one of claims 14-21, further comprising an adjuvant, for use in vaccination for the prevention of a malignancy."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["Vaccine suitable for use in children, in particular adapted for use in infants and/or babies, comprising a peptide or polypeptide according to any one of claims 14-21."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["Vaccine of claim 23 in unit dosage form, wherein the unit dosage is 10% - 90% of the unit dosage for adults, preferably 20% to 80%, more preferably 30% to 70% and most preferably 40% to 60%."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["Vaccine of claim 23, comprising two or more different peptides according to any one of claims 14 to 19, two or more different polypeptides according to claims 20 or 21, or at least one peptide according to any one of claims 14 to 19 and at least one polypeptide according to claims 20 or 21."],"number":25,"annotation":false,"title":false,"claim":true},{"lines":["DNA-based vaccine comprising an expression construct comprising a promoter functional in eukaryotic cells and a polynucleotide encoding at least one peptide according to any one of claims 14 to 19 and/or at least one polypeptide according to claims 20 or 21, wherein said polynucleotide is positioned sense to and under the control of said promoter, for use in vaccination for the prevention of a malignancy."],"number":26,"annotation":false,"title":false,"claim":true},{"lines":["DNA-based vaccine of claim 26, wherein the polynucleotide encodes 5 to 30 copies, preferably 10 to 20 copies, of the peptide according to any one of claims 14 to 19 and/or 2 to 10 copies of the polypeptide according to claims 20 or 21."],"number":27,"annotation":false,"title":false,"claim":true},{"lines":["DNA-based vaccine of claim 27, wherein the multiple copies of said peptide or said polypeptide are encoded in the context of a single fusion polypeptide."],"number":28,"annotation":false,"title":false,"claim":true},{"lines":["DNA-based vaccine of any one of claims 26 to 28, further comprising a polypeptide of modified vacciniavirus Ankara (MVA), canary-pox-virus, adenovirus, sindbis-Virus, dengue virus, yellow fever virus, measles virus, sendai virus, polio virus, papilloma virus, rota virus, Venezuelan encephalitis virus, semliki forest virus and hepatitis A virus."],"number":29,"annotation":false,"title":false,"claim":true},{"lines":["DNA-based vaccine of any one of claims 26 to 29, wherein the DNA-based vaccine is in the form of a viral vector, in particular in the form of a modified vacciniavirus Ankara (MVA), canary-pox-virus, adenovirus, sindbis-Virus, dengue virus, yellow fever virus, measles virus, sendai virus, polio virus, papilloma virus, rota virus, Venezuelan encephalitis virus, semliki forest virus and hepatitis A virus. Preferred are vectors of the pox group, papilloma, Venezuelan encephalitis virus, Semliki forest virus, adeno virus and hepatitis A virus."],"number":30,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}